Drug-drug interactions between antiseizure medications and antipsychotic medications: a narrative review and expert opinion
- 2 November 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 19 (11) , 829-847
Abstract
Antiseizure medications (ASMs) and antipsychotic drugs are frequently coadministered with the potential for drug-drug interactions. Interactions may either be pharmacokinetic or pharmacodynamic, resulting in a decrease or increase in efficacy and/or an increase or decrease in adverse effects. The clinical evidence for pharmacokinetic and pharmacodynamic interactions between ASMs and antipsychotics is reviewed based on the results of a literature search in MEDLINE conducted in April 2023. There is now extensive published evidence for the clinical importance of interactions between ASMs and antipsychotics. Enzyme-inducing ASMs can decrease blood concentrations of many of the antipsychotics. There is also evidence that enzyme-inhibiting ASMs can increase antipsychotic blood concentrations. Similarly, there is limited evidence showing that antipsychotic drugs may affect the blood concentrations of ASMs through pharmacokinetic interactions. There is less available evidence for pharmacodynamic interactions, but these can also be important, as can displacement from protein binding. The lack of published evidence for an interaction should not be interpreted as meaning that the given interaction does not occur; the evidence is building continually. There is no substitute for careful patient monitoring and sound clinical judgment.Keywords
Funding Information
- No funding
This publication has 109 references indexed in Scilit:
- PharmGKB summaryPharmacogenetics and Genomics, 2012
- Possible drug–drug interaction between quetiapine and lamotrigine – evidence from a Swedish TDM databaseBritish Journal of Clinical Pharmacology, 2011
- Quetiapine and Drug InteractionsThe Journal of Clinical Psychiatry, 2007
- Interactions between Antiepileptic and Antipsychotic DrugsDrug Safety, 2006
- Pharmacokinetic Interactions of TopiramateClinical Pharmacokinetics, 2004
- Population Pharmacokinetics of Haloperidol Using Routine Clinical Pharmacokinetic Data in Japanese PatientsClinical Pharmacokinetics, 2002
- Clinical Pharmacokinetics of QuetiapineClinical Pharmacokinetics, 2001
- Pharmacokinetics of HaloperidolClinical Pharmacokinetics, 1999
- OlanzapineClinical Pharmacokinetics, 1999
- Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man.British Journal of Clinical Pharmacology, 1975